Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary...

by Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel Berg, James S. Garner, Don S. Dizon
Published 2021-06-01

Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin

by Joseph W Po, Aflah Roohullah, David Lynch, Anna DeFazio, Michelle Harrison, Paul R Harnett, Catherine Kennedy, Paul de Souza, Therese M Becker
Published 2018-06-01

Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.

by Catherine Emmanuel, Natalie Gava, Catherine Kennedy, Rosemary L Balleine, Raghwa Sharma, Gerard Wain, Alison Brand, Russell Hogg, Dariush Etemadmoghadam, Joshy George, Australian Ovarian Cancer Study Group, Michael J Birrer, Christine L Clarke, Georgia Chenevix-Trench, David D L Bowtell, Paul R Harnett, Anna deFazio
Published 2011-01-01

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

by Bo Gao, Yi Lu, Annemieke J. M. Nieuweboer, Hongmei Xu, Jonathan Beesley, Ingrid Boere, Anne-Joy M. de Graan, Peter de Bruijn, Howard Gurney, Catherine J. Kennedy, Yoke-Eng Chiew, Sharon E. Johnatty, Philip Beale, Michelle Harrison, Craig Luccarini, Don Conroy, Ron H. J. Mathijssen, Paul R. Harnett, Rosemary L. Balleine, Georgia Chenevix-Trench, Stuart Macgregor, Anna de Fazio
Published 2018-01-01